Create account

Coverage dated November 12, 2026

Roche is planning to call its experimental breast cancer pill Wilserdly

Headline from Quartz

Roche has registered the name in multiple jurisdictions as the FDA reviews two applications, with a first decision due Nov. 30

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. Bloomberg

    Roche Plans Wilserdly as Brand Name for Its Breast-Cancer Pill (opens Bloomberg)

    Published

    Bloomberg's feed description

    Roche Holding AG plans to call its new breast-cancer pill Wilserdly, and has registered the name in multiple jurisdictions ahead of the potential approval of a drug it hopes will dominate a new way of treating the disease.

  2. Quartz

    Roche is planning to call its experimental breast cancer pill Wilserdly (opens Quartz)

    Published

    Quartz's feed description

    Roche has registered the name in multiple jurisdictions as the FDA reviews two applications, with a first decision due Nov. 30

Roche is planning to call its experimental breast cancer pill Wilserdly | Since Then